Sprycel (dasatinib) - Chronic Myeloid Leukemia
''Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibband sold under the trade name Sprycel. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitorapproved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastaticmelanoma.
The drug is named after one of the inventor chemists, Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.''
Extract of Wikipedia
The drug is named after one of the inventor chemists, Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.''
Extract of Wikipedia
SITES
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives
January 15, 2012, PubLMed
Leukemia drug Sprycel linked to dangerous side effect
August 30, 2011, The Canadian Press
Risk of pulmonary arterial hypertension with Sprycel (dasatinib)
August 16, 2011, CBG-MEB
Dasatinib Shows Superior Efficacy and Acceptable Tolerability, Supporting First-Line Use in Newly Diagnosed CML-CP
June 3 , 2011, Monthly Prescribing Reference
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
October 28, 2010, FierceBiotech
Dasatinib, an immunomodulator?
August 2010, Journal Blood
Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday
Dr. Sonali Smith talks about some of the advances in chronic myeloid leukemia care coming out of the 2010 ASCO Annual Meeting |
New leukemia treatment - Sprycel
|
